TGFβ represses PDK4 expression, and PDK4 inhibition was sufficient to drive EMT and promote erlotinib resistance in epidermal growth factor receptor (EGFR) mutant lung cancer cells (Fig. 2). This evidence concerns the gene PDK4 and lung carcinoma.